QRxPharma hits on right dose
Monday, 20 April, 2009
Sydney’s QRxPharma has completed a Phase III pilot study comparing the efficacy of its lead dual-opioid with its constituent parts.
The lead drug, MoxDuo IR, a combination of morphine and oxycodone, was found to reduce pain significantly more than its component parts, and had fewer side effects than the two drugs administered together.
QRxPharama is in Phase III trials with the immediate release version of MoxDuo and in earlier stage trials for controlled release and intravenous administration. It is also being compared against Percocet in joint replacement surgery.
Besides its analgesia work, the company is also developing a known compound to activate the chaperone protein Torsin for neurological diseases such as Parkinson’s, and has an anti-haemorrhagic and an anti-coagulant derived from venoms in pre-clinical trials.
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
Biotech manufacturing facility opens in Brisbane
ENTRI, a purpose-built multimodal facility which will enable biotech companies to manufacture...
